Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech
Gilead CEO Daniel O’Day has nabbed another immuno-oncology partner in his quest to remake the biotech’s cancer division, inking an up-to $1.5 billion deal with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.